2017 FDA Peptide Harvest
by
Othman Al Musaimi 1,2,†
, Danah Al Shaer 1,2,†, Beatriz G. De la Torre 3,* and Fernando Albericio 2,4,5,*
Othman Al Musaimi 1,2,†, Danah Al Shaer 1,2,†, Beatriz G. De la Torre 3,* and Fernando Albericio 2,4,5,*
1
College of Health Sciences, University of KwaZulu-Natal, Durban 4000, South Africa
2
School of Chemistry, University of KwaZulu-Natal, Durban 4001, South Africa
3
KRISP, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa
4
CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, University of Barcelona, 08028 Barcelona, Spain
5
Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Pharmaceuticals 2018, 11(2), 42; https://doi.org/10.3390/ph11020042
Received: 9 April 2018 / Revised: 30 April 2018 / Accepted: 3 May 2018 / Published: 7 May 2018
2017 was an excellent year in terms of new drugs (chemical entities and biologics) approved by the FDA, with a total of 46. In turn, one of the highlights was the number of peptides (six) included in this list. Here, the six peptides are analyzed in terms of chemical structure, synthetic strategy used for their production, source, therapeutic use, and mode of action.
View Full-Text
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Al Musaimi, O.; Al Shaer, D.; De la Torre, B.G.; Albericio, F. 2017 FDA Peptide Harvest. Pharmaceuticals 2018, 11, 42.
Show more citation formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
